A single CRISPR construct recognising a key part of the EBV DNA was able to deactivate the virus in 40-60% of cells harbouring EBV infection. When two different CRISPRs, each targeting slightly different parts of the EBV DNA, were used simultaneously the viral deactivation rate rose to more than 95%